Intestinal glucagon-like peptide-1 in hypoglycemic counterregulation for type 1 diabetes management

doi:10.4239/wjd.v15.i12.2380

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (380)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

296

Sum=317

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=44

Dec 15, 2024 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Diabetes. Dec 15, 2024; 15(12): 2380-2383
Published online Dec 15, 2024. doi: 10.4239/wjd.v15.i12.2380

Intestinal glucagon-like peptide-1 in hypoglycemic counterregulation for type 1 diabetes management

Ke-Xin Zhang, Cheng-Xia Kan, Yu-Qun Wang, Ning-Ning Hou, Xiao-Dong Sun

Ke-Xin Zhang, Cheng-Xia Kan, Yu-Qun Wang, Ning-Ning Hou, Xiao-Dong Sun, Department of Endocrinology and Metabolism, The Affiliated Hospital of Shandong Second Medical University, Weifang 261031, Shandong Province, China

Author contributions: All the authors contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Xiao-Dong Sun, MD, PhD, Chief Doctor, Department of Endocrinology and Metabolism, The Affiliated Hospital of Shandong Second Medical University, No. 2428 Yuhe Road, Weifang 261031, Shandong Province, China. xiaodong.sun@sdsmu.edu.cn

Received: July 8, 2024
Revised: September 13, 2024
Accepted: October 12, 2024
Published online: December 15, 2024
Processing time: 132 Days and 17.7 Hours

Core Tip

Core Tip: Elevated intestinal glucagon-like peptide-1 impairs hypoglycemic counterregulation in type 1 diabetes by reducing glucagon and adrenaline secretion. This highlights the need for a balanced approach to glucagon-like peptide-1-based therapies, considering both glycemic control and the risk of hypoglycemia.